164 related articles for article (PubMed ID: 2731181)
21. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
22. Polymorphic oxidation of debrisoquine in bladder cancer.
Benítez J; Ladero JM; Fernández-Gundín MJ; Llerena A; Cobaleda J; Martínez C; Muñoz JJ; Vargas E; Prados J; González-Rozas F
Ann Med; 1990 Jun; 22(3):157-60. PubMed ID: 2393550
[TBL] [Abstract][Full Text] [Related]
23. [When contronted with a new lung cancer case, are we often thinking of and searching for an occupational etiology?].
Chiriac CF; Gavriliţă L
Pneumologia; 2002; 51(4):272-6. PubMed ID: 12693165
[TBL] [Abstract][Full Text] [Related]
24. Occupational lung cancer and smoking: a review in the light of current theories of carcinogenesis.
Chovil AC
Can Med Assoc J; 1979 Sep; 121(5):548-50, 553-5. PubMed ID: 387195
[TBL] [Abstract][Full Text] [Related]
25. Debrisoquine metabolism and lung cancer risk.
Shaw GL; Falk RT; Deslauriers J; Frame JN; Nesbitt JC; Pass HI; Issaq HJ; Hoover RN; Tucker MA
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):41-8. PubMed ID: 7894323
[TBL] [Abstract][Full Text] [Related]
26. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
Wanwimolruk S; Patamasucon P; Lee EJ
Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
[TBL] [Abstract][Full Text] [Related]
27. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
Brøsen K; Gram LF; Haghfelt T; Bertilsson L
Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
[TBL] [Abstract][Full Text] [Related]
28. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
Sloan TP; Idle JR; Smith RL
Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
[TBL] [Abstract][Full Text] [Related]
29. [The missions of the Occupational Diseases Fund. Under-claim and recognition of occupational lung cancer, in particular those related to asbestos].
Thimpont J; Paquier L; Dumortier P; Farr P; De Brouwer C; Strauss P; De Vuyst P
Rev Med Brux; 2009 Sep; 30(4):318-25. PubMed ID: 19899379
[TBL] [Abstract][Full Text] [Related]
30. Genetically determined debrisoquine oxidation capacity in bladder cancer.
Cartwright RA; Philip PA; Rogers HJ; Glashan RW
Carcinogenesis; 1984 Sep; 5(9):1191-2. PubMed ID: 6467507
[TBL] [Abstract][Full Text] [Related]
31. Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis.
Ritchie JC; Idle JR
IARC Sci Publ; 1982; (39):381-94. PubMed ID: 7152615
[TBL] [Abstract][Full Text] [Related]
32. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.
Ayesh R; Idle JR; Ritchie JC; Crothers MJ; Hetzel MR
Nature; 1984 Nov 8-14; 312(5990):169-70. PubMed ID: 6504125
[TBL] [Abstract][Full Text] [Related]
33. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.
Vincent-Viry M; Muller J; Fournier B; Galteau MM; Siest G
Clin Chem; 1991 Mar; 37(3):327-32. PubMed ID: 2004438
[TBL] [Abstract][Full Text] [Related]
34. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
Caporaso NE; Shields PG; Landi MT; Shaw GL; Tucker MA; Hoover R; Sugimura H; Weston A; Harris CC
Environ Health Perspect; 1992 Nov; 98():101-5. PubMed ID: 1362537
[TBL] [Abstract][Full Text] [Related]
35. Socioeconomic status and lung cancer incidence in men in The Netherlands: is there a role for occupational exposure?
van Loon AJ; Goldbohm RA; Kant IJ; Swaen GM; Kremer AM; van den Brandt PA
J Epidemiol Community Health; 1997 Feb; 51(1):24-9. PubMed ID: 9135784
[TBL] [Abstract][Full Text] [Related]
36. Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendations.
Delva F; Margery J; Laurent F; Petitprez K; Pairon JC;
BMC Public Health; 2017 Feb; 17(1):191. PubMed ID: 28193266
[TBL] [Abstract][Full Text] [Related]
37. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.
Sommers DK; Moncrieff J; Avenant J
Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305
[TBL] [Abstract][Full Text] [Related]
38. Oxidation phenotyping with debrisoquine in Germany (East).
Zschiesche M; Hanke W; Siegmund W; Franke G; Wilke A
Pharmazie; 1990 Dec; 45(12):920-1. PubMed ID: 2100800
[TBL] [Abstract][Full Text] [Related]
39. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
[TBL] [Abstract][Full Text] [Related]
40. Debrisoquine oxidation phenotype during neuroleptic monotherapy.
Spina E; Martines C; Caputi AP; Cobaleda J; Piñas B; Carrillo JA; Benitez J
Eur J Clin Pharmacol; 1991; 41(5):467-70. PubMed ID: 1684751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
